Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA to review Regeneron’s linvoseltamab BLA for multiple myeloma treatment
Linvoseltamab is intended for use in MM patients who have undergone a minimum of four lines of therapy previously or those who received three lines of treatment and
Linvoseltamab is intended for use in MM patients who have undergone a minimum of four lines of therapy previously or those who received three lines of treatment and
The partnership will utilise the Pb-212 production technology and radionuclide development infrastructure of AdvanCell alongside Lilly’s expertise in drug development and drug candidate programmes. It will support the
In March last year, Fennec Pharmaceuticals entered an exclusive licensing agreement, granting Norgine commercialisation rights for the injection in Australia, New Zealand, and Europe. Under this agreement, Fennec
This expansion includes exclusive distribution agreements as well as new market authorisation transfers. The current agreement in Japan follows the last year agreement between the two companies for
The collaboration brings together LEO Pharma’s “expertise” in medical dermatology and DEBRA Research’s pharmaceutical experience to develop novel medicines for this condition. DEBRA Research managing director Prof Hubert Truebel
Concurrently, the company also secured a funding of $27m in Series B round. The proceeds are set to be utilised for progressing the therapy through a Phase I
The acquisition primarily comprises cash payments, with a smaller portion in the form of BioNTech American Depositary Shares. In addition, there are potential performance-based payments of up to
The decision is based on outcomes from the Phase III CheckMate -9DW trial. According to the outcomes of the trial presented by the company in June last year,
This places the company’s valuation at $525m. Transformation Capital led the funding round, with participation from current investors like World Innovation Lab, OCV Partners, UP2398, Khosla Ventures, Cone
Additionally, the company is on track to submit a marketing authorisation application (MAA) to the European Medicines Agency (EMA) in the first quarter of this year. The Division